Latest Regulatory Pathways News

Aureka Limited extends its Victorian gold resource ambitions with strong drilling results at Irvine and Comstock, backed by fresh geophysical data and secured tenure.

TG Metals reports exceptional metallurgical results from heap leach testwork on Laterite gold at Van Uden, unlocking a potential low-cost, near-term cashflow opportunity from over one million tonnes of surface material.

NeuroScientific Biopharmaceuticals reported positive clinical responses in its StemSmart™ Special Access Program for fistulising Crohn’s disease and has initiated manufacturing technology transfer to support Phase 2 trials planned for late 2026.

Jade Gas Holdings has completed its appraisal program at the Tavan Tolgoi coal bed methane project, preparing to lodge its maiden gas reserve booking and advance development plans backed by fresh capital.

Meteoric Resources has reported strong pilot plant performance and advanced feasibility work at its Caldeira rare earths project, alongside a $50 million non-binding financing letter from Export Finance Australia and robust Brazilian government backing.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.

Acrux pivots from generics to developing a Female Testosterone therapy for HSDD, leveraging FDA feedback and a strong US market opportunity.

Nexsen Limited has cleared a major FDA regulatory hurdle for its StrepSure rapid Group B Streptococcus test, confirmed a clear 510(k) submission pathway, and secured over A$1.7 million in non-dilutive grants to expand clinical validation and market rollout in Asia-Pacific and neonatal diagnostics.

Entropy Neurodynamics has reported encouraging early clinical outcomes from its pioneering intravenous psilocin therapy for Binge Eating Disorder, alongside a patent grant that strengthens its intellectual property moat.

Dimerix’s blinded review of its pivotal ACTION3 Phase 3 trial confirms over 90% statistical power to detect DMX-200’s effect on proteinuria, reinforcing the study’s design and regulatory pathway.

Orthocell’s latest Remplir™ Real World Evidence study reveals an 89.7% treatment success rate across 78 nerve repair procedures, reinforcing its clinical strength and fueling US and European market growth plans.